Aim: Despite continuing research into Alzheimer's disease (AD), its pathological mechanisms and modulating factors remain unknown. Several genes influence AD pathogenesis by affecting inflammatory pathways. Myocyte-enhancer factor 2C (MEF2C) is one such candidate gene for AD.
A LZHEIMER'S DISEASE (AD) IS the most common cause of cognitive disorders in elderly adults. In 2013, 35.6 million patients worldwide had AD, and the number of patients with AD is estimated to triple by 2050. 1 AD is characterized by specific clinical symptoms and histopathological features. Clinical symptoms include impaired learning and memory and declines in other cognitive functions. [2] [3] [4] Histopathological features include extracellular amyloid deposits that consist of amyloid beta (Aβ) and neurofibrillary tangles that occur due to intracellular accumulation of the hyperphosphorylated microtubule-associated protein, tau. [5] [6] [7] However, not all of the symptoms and features of AD can be explained by accumulation of Aβ and/or hyperphosphorylated tau. Several reports have shown no significant correlation between cognitive decline and the amount of Aβ in the brain. 8, 9 Recently, genome-wide association studies (GWAS) of lateonset AD revealed that some genes in inflammatory pathways are associated with AD pathogenesis. [10] [11] [12] [13] Myocyte-enhancer factor 2C (MEF2C) is a candidate gene that was identified by GWAS. MEF2C is involved in inflammatory processes and plays a critical role in B-cell proliferation upon antigen stimulation, which occurs following foreign antigen binding to B cell receptors.
14 MEF2C enhances the expression of DNA repair molecules and recombination factors in B-cell progenitors and promotes cell survival. 15 A non-competitive N-methyl-D-aspartate receptor antagonist, memantine, reduces B-cell proliferation 16 and is used to treat the symptoms of AD. These data suggest the presence of a relation between B cell immunological responses and AD. However, there are no studies evaluating the effect of memantine on MEF2C and this is an open area of research. Moreover, MEF2C is highly expressed in brain regions related to learning and memory, such as the frontal cortex, entorhinal cortex, dentate gyrus, and amygdala. 17 Thus, MEF2C may be associated with the pathogenesis of AD, and if a relation exists, mRNA expression levels in leukocytes from AD subjects may be changed. In addition, epigenetic changes, including DNA methylation, which is involved in neuropsychiatric conditions, may influence MEF2C mRNA expression in AD. 18 Therefore, investigation of MEF2C in peripheral leukocytes from AD patients may help elucidate AD pathogenesis, and MEF2C may become a convenient clinical biomarker. [19] [20] [21] [22] However, the relations between MEF2C expression levels and methylation rates in leukocytes have not been examined.
The aim of our study was to investigate the relation between MEF2C expression in leukocytes and psychological symptoms in Japanese AD subjects.
METHODS Subjects
Demographic data of participants are shown in Table 1 . Fifty AD subjects were enrolled who were outpatients in Ehime University Hospital, Zaidan Niihama Hospital, or Kuroda Hospital, Ehime, Japan. AD subjects were diagnosed with probable AD dementia according to the Aging/Alzheimer's Association criteria 23 and were living with at least one caregiver. We evaluated the cognitive functions of AD subjects with the Mini Mental State Examination (MMSE) 24 and the Alzheimer's Disease Assessment Scale (ADAS). 25 Symptoms of depression were evaluated with the Montgomery-Åsberg Depression Rating Scale (MADRS). 26 We also evaluated cognitive function with the Clinical Dementia Rating (CDR) 27 and behavioral disturbances with the Neuropsychiatric Inventory (NPI). 28 Fifty healthy subjects without cognitive or psychiatric disorders were enrolled as controls. All participants provided written informed consent forms approved by the institutional ethics committees of Ehime University Hospital, Zaidan Niihama Hospital, and Kuroda Hospital.
Blood sample collection and processing of complementary DNA and genomic DNA RNA samples were obtained from peripheral blood samples using PaxGene Blood RNA Systems tubes (BD, Tokyo, Japan) according to the manufacturer's protocol. For each 40-μL reaction, we used 1.0 μg RNA to synthesize complementary DNA (cDNA) with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). For genomic DNA (gDNA), peripheral blood samples were collected in potassium ethylenediaminetetraacetic acid tubes, and gDNA was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan) according to the manufacturer's protocol.
Gene expression
Real-time quantitative polymerase chain reaction (PCR) was performed in duplicate to analyze mRNA expression. We used the StepOnePlus Real-Time PCR System (Applied Biosystems). The specific TaqMan probes were Hs00231149_m1 for MEF2C and Hs99999905_m1 for GAPDH (Applied Biosystems). We used GAPDH as a housekeeping gene because previous studies, including ours, have consistently identified GAPDH as a suitable housekeeping gene for leukocyte gene expression analysis using the Paxgene blood RNA system. [29] [30] [31] [32] We used the ΔΔCt method and StepOne software (Applied Biosystems) to calculate expression levels. 
Genotyping analysis
The single-nucleotide polymorphisms (SNP), rs429358 (NG_007084.2; assayID: C__3084793_ 20) and rs7412 (NG_007084.2; assay ID: C__904 973_10, TaqMan Assays, Applied Biosystems) were used to determine the apolipoprotein E (APOE) isoform, as well. PCR was performed with TaqMan PCR Master Mix, TaqMan SNP genotyping assay, 10 ng gDNA, and ultrapure water to a final reaction volume of 6 μL in each well of an optical plate. Allelic discrimination was determined using the StepOnePlus Real-Time PCR System and analyzed using StepOnePlus software.
Bisulfite conversion and pyrosequencing
We used JASPAR (http://jaspar.binf.ku.dk/) to select four CpG sites predicted to bind major transcription factors. First, we analyzed the number of potential transcription factor binding sites in the promoter (from exon 1 to −200 bp), intron 1, intron 2, and intron 3 of MEF2C. Then, we focused on four CpG sites in intron 1 where the largest number of transcription factors was predicted to bind with a high score (predictive value > 5). The position of the four CpG sites in the MEF2C promoter region and the putative binding sites of these transcription factors are depicted in Figure 1 . C. The PCR products were sequenced using PyroMark Q24 Advanced (Qiagen) and the sequencing primer, 5 0 -AGTGATAGAAATAGGTGTAT-3 0 . Methylation rates at each CpG site were quantified in duplicate using PyroMark Q24 Advanced Software (Qiagen).
Statistical analysis
We performed statistical analyses using SPSS 22.0 (IBM Japan, Tokyo, Japan) and EZR 1.33. 33 Sex differences and the APOE genotype were analyzed with Pearson's χ 2 -test. We performed a test of normality with the Shapiro-Wilk test. We performed the Mann-Whitney U-test for comparisons of MEF2C mRNA expression and each CpG methylation rate between AD and control subjects and for comparisons of MEF2C mRNA showing the location of the myocyte-enhancer factor 2C (MEF2C) region we analyzed. CpG sites predicted to bind transcription factors are depicted under the sequence. Correlations among the four CpG were analyzed with the Spearman's rank correlation coefficient. Statistical significance was defined as P = 0.0125 using Bonferroni correction. AD, Alzheimer's disease subjects; F, forward primer; R, reverse primer; S, sequencing primer. expression with sex, APOE genotypes, and donepezil treatment. We performed the Spearman's rank correlation to detect correlations between MEF2C mRNA expression and age, duration of illness, MMSE, ADAS, MADRS, NPI, and methylation rates at each CpG site. We also performed the Kruskal-Wallis test with the post-hoc Steel-Dwass test to detect correlations between MEF2C mRNA expression and CDR. We defined statistical significance at the 95% level (P = 0.05).
RESULTS

Participant characteristics
Demographic data and APOE genotypes of all the participants are shown in Table 2 . Age did not differ between AD subjects and control subjects. Significantly more AD subjects than control subjects possessed the ε4 allele of APOE (odds ratio [OR] = 7.2, 95% confidence interval [CI]: 2.71-19.09, Cramer's V = 0.172, P < 0.001). We found no allele effects of APOE ε4 on cognition or neuropsychiatric symptoms assessed with MMSE (P = 0.899), ADAS (P = 0.375), and CDR (P = 0.232). Clinical characteristics and results of psychological tests in AD subjects are shown in Table 2 .
MEF2C mRNA expression levels MEF2C mRNA expression levels in AD subjects were significantly lower than those in control subjects (0.86 AE 0.25 vs 0.99 AE 0.27, respectively, P = 0.007, Z = −2.709, effect size = −0.271, Fig. 2 ). MEF2C mRNA expression levels were not correlated with sex (AD subjects, P = 0.699; control subjects, P = 0.150), age (AD subjects, P = 0.784; control subjects, P = 0.386), duration of illness (AD subjects, P = 0.417), APOE genotype (AD subjects, P = 0.514; control subjects, P = 0.685), or donepezil treatment (AD subjects, P = 0.093). MEF2C mRNA expression levels in AD subjects were significantly correlated with the total scores of MMSE (r = 0.324, 95%CI: 0.042-0.559, P = 0.02, Fig. 3 ), ADAS (r = −0.345, 95%CI: −0.622 to 0.008, P = 0.049, Fig. 4) , and the Recall subscale of the MMSE (P = 0.02). MEF2C mRNA expression levels were not correlated with NPI (P = 0.449) or CDR (P = 0.1).
Methylation status
Methylation rates are shown in Figure 1 . The methylation rates were as follows: AD subjects, CpG1 = . No significant differences were found in methylation rates at any of the four CpG sites between AD and control subjects (CpG1, P = 0.621; CpG2, P = 0.203; CpG3, P = 0.372; CpG4, P = 0.170). We also found no significant correlations between methylation rates and MEF2C mRNA expression levels (CpG1, P = 0.261; CpG2, P = 0.350; CpG3, P = 0.814; CpG4, P = 0.533).
DISCUSSION
We showed lower MEF2C mRNA expression levels in AD subjects compared with control subjects. MEF2C mRNA expression levels were correlated with cognitive function in AD subjects, and were not correlated with sex, age, duration of illness, or donepezil treatment. No significant differences were found in methylation rates between AD and control subjects. Although ε4 allele of APOE has been considered as the symptom-modifying factor of late-onset AD, [34] [35] [36] we found no allele effects of APOE ε4 on cognition assessed with MMSE, ADAS, or CDR. Thus, MEF2C mRNA expression in AD patients may be more sensitive to cognitive function than APOE genotypes. Although the inflammatory role of APOE ε4 has been an interesting topic in recent years, there are no clinical studies indicating a direct pathophysiological relationship between APOE ε4 and MEF2C.
Some reports have shown that the MEF2 family proteins protect neurons from apoptotic death [37] [38] [39] and regulate dendrite morphogenesis and differentiation of post-synaptic structures. 40 MEF2 family members also regulate the number of synaptic contacts that a neuron receives. 41 Although the definite functions and roles of MEF2 family members have not been thoroughly investigated, MEF2 family members likely play an important role in synaptic plasticity and influence learning and memory. 42 MEF2C is more widely expressed and regulates diverse transcriptional events, such as the development and differentiation of many tissues. 42 In addition, MEF2C is found to be highly expressed in B cells of the spleen and lymph node 43 and plays a critical role in B cell proliferation upon antigen stimulation. 14, 44 Recently, MEF2C was reported to protect B lymphopoiesis during stress by ensuring proper expression of genes that encode DNA repair and B-cell factors. 15 Interestingly, the noncompetitive N-methyl-D-aspartate receptor antagonist, memantine, also attenuates adaptive as well as innate B cell signaling and may be useful to target B cells under pathological inflammatory conditions like AD.
16 MEF2C is also reported to be a central transcriptional component of the innate immune response. 45 In the adult human brain, MEF2C is highly expressed in brain regions involved in learning and memory, such as the frontal cortex, entorhinal cortex, dentate gyrus, and amygdala. 15 Thus, it is plausible that MEF2C is also involved in the inflammatory process in the brains of AD through regulating microglia proliferation. 5 Decreased expression of MEF2C in our results may reflect impaired protection of B cells and dysregulated microglial proliferation. Morphologically, a significant relation is present between MEF2C mRNA expression in certain brain regions and AD risk allele. 46 From these reports, we hypothesized that MEF2C mRNA expression was correlated with neuronal activities in regions related to cognitive functions and that lower MEF2C mRNA expression levels in leukocytes of AD subjects reflect MEF2C activity in the brain.
We found that MEF2C mRNA expression levels in leukocytes were significantly correlated with total MMSE, the Recall subscale in MMSE, and ADAS in AD subjects. The greater the cognitive decline, the lower the MEF2C mRNA expression. Consistent with our results, a meta-analysis of GWAS revealed a significant association between general cognitive © 2017 The Authors Psychiatry and Clinical Neurosciences © 2017 Japanese Society of Psychiatry and Neurology functional decline in middle-aged and older adults and a MEF2C genetic variant. 47 Because the first aspect of cognition that is impaired is recall, 42 we suggest that MEF2C mRNA expression levels in leukocytes may be not only a diagnostic biomarker for AD but also a biomarker for early detection of cognitive decline, such as mild cognitive impairment.
Although methylation rates in the promoter region generally influence gene expression levels, 45 we found no significant change in the methylation ratio in the upstream region of MEF2C exon 1 in the blood of AD patients, and no correlation between the methylation ratio and MEF2C mRNA expression. Generally, an inverse relation is present between CpG methylation and transcriptional activity. 48, 49 In the promoter region, hypermethylation is usually related to transcriptional silencing. 50, 51 Although we selected target CpG sites that may theoretically bind major transcription factors in silico, an in vitro verification study, such as a luciferase-reported assay, is needed to confirm that these target CpG sites are bound by transcription factors and regulate gene expression. Other promoter regions or introns 21, 22, 52 may regulate MEF2C mRNA expression.
Our study has several limitations. First, we did not examine MMSE or ADAS in control subjects. To determine whether MEF2C mRNA expression may be a biomarker for early detection of AD, we should examine controls and subjects with mild cognitive impairment. Neuroimaging studies examining critical regional metabolism responsible for cognition (e.g., magnetic resonance spectroscopy) and MEF2C levels in AD or mild cognitive impairment patients may be informative. CSF studies examining MEF2C levels in AD or mild cognitive impairment patients may also be informative. Second, the sample size was relatively small. Further research with a larger sample size will be necessary to confirm our findings. In addition, whether MEF2C expression in the brain is in good agreement with MEF2C mRNA expression in leukocytes remains to be clarified. Third, as our sample size was quite small, we did not take multiple comparisons into consideration, thus caution should be given to the findings in this study.
In summary, our results suggest that lower MEF2C mRNA expression levels in leukocytes may be a diagnostic marker for AD, and a decrease in MEF2C may reflect cognitive decline regardless of the promoter methylation status in AD subjects.
